Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Phase 3

Completed

Conditions: Community Acquired Pneumonia

Interventions: Drug: lefamulin
Drug: Moxifloxacin
Drug: Linezolid

First Posted Date: 2015-09-24

Last Posted Date: 2019-10-23

Lead Sponsor: Nabriva Therapeutics AG

Target Recruit Count: 551

Registration Number: NCT02559310

Locations: 🇦🇷
Site 3005, La Plata, Buenos Aires, Argentina
🇦🇷
Site 3007, Córdoba, Argentina
🇦🇷
Site 3001, Córdoba, Argentina

and more 96 locations

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo (for fedovapagon)
Drug: Fedovapagon
Drug: Moxifloxacin

First Posted Date: 2015-09-01

Last Posted Date: 2016-01-06

Lead Sponsor: Vantia Ltd

Target Recruit Count: 43

Registration Number: NCT02537288

Locations: 🇩🇪
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Phase 3

Completed

Conditions: Community-Acquired Infections
Bacterial Pneumonia

Interventions: Drug: Moxifloxacin
Drug: Omadacycline

First Posted Date: 2015-08-24

Last Posted Date: 2019-01-16

Lead Sponsor: Paratek Pharmaceuticals Inc

Target Recruit Count: 774

Registration Number: NCT02531438

Locations: 🇵🇪
Site 481, Lima, Peru
🇨🇿
Site 411, Praha 10, Czechia
🇧🇬
Site 303, Pernik, Bulgaria

and more 137 locations

Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: FYU-981
Drug: Moxifloxacin Placebo
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2015-08-05

Last Posted Date: 2017-09-08

Lead Sponsor: Fuji Yakuhin Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT02515864

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CXA-101/tazobactam
Drug: placebo
Drug: Moxifloxacin

First Posted Date: 2015-07-27

Last Posted Date: 2017-01-26

Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 52

Registration Number: NCT02508753

Locations: 🇺🇸
Cetero Reserach, Fargo, North Dakota, United States

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin
Drug: ALKS 5461
Drug: Placebo

First Posted Date: 2015-06-24

Last Posted Date: 2015-11-23

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 129

Registration Number: NCT02479308

Locations: 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis
Multidrug Resistant Tuberculosis
Extensively-drug Resistant Tuberculosis

Interventions: Drug: Pyrazinamide
Drug: Linezolid
Drug: Ethionamide
Drug: Bedaquiline
Drug: Terizidone
Drug: Levofloxacin
Drug: Moxifloxacin
Drug: Kanamycin
Drug: Isoniazid

First Posted Date: 2015-05-27

Last Posted Date: 2021-09-29

Lead Sponsor: University of Cape Town

Target Recruit Count: 154

Registration Number: NCT02454205

Locations: 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Phase 3

Completed

Conditions: MDR-TB

Interventions: Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
Drug: Moxifloxacin
Drug: Clofazimine
Drug: Ethambutol
Drug: Pyrazinamide
Drug: Isoniazid
Drug: Prothionamide
Drug: Bedaquiline
Drug: Kanamycin
Drug: Levofloxacin

First Posted Date: 2015-04-06

Last Posted Date: 2023-09-28

Lead Sponsor: IUATLD, Inc

Target Recruit Count: 588

Registration Number: NCT02409290

Locations: 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹
St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪
JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 10 locations

The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection

Not Applicable

Terminated

Conditions: Helicobacter Infection

Interventions: Drug: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor)
Procedure: H. pylori culture and antimicrobial susceptibility testing
Drug: 7 days tailored therapy Proton Pump Inhibitor
Drug: Metronidazole
Drug: Tetracycline
Drug: Moxifloxacin
Drug: tripotassium dicitrate bismuthate
Drug: Amoxicillin

First Posted Date: 2015-02-10

Last Posted Date: 2023-04-13

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 370

Registration Number: NCT02359331

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TRV130
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2015-01-22

Last Posted Date: 2017-05-12

Lead Sponsor: Trevena Inc.

Target Recruit Count: 63

Registration Number: NCT02344303

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy